Compare NPFD & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NPFD | IPSC |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.1M | 441.9M |
| IPO Year | 2021 | 2021 |
| Metric | NPFD | IPSC |
|---|---|---|
| Price | $18.73 | $2.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.25 |
| AVG Volume (30 Days) | 52.8K | ★ 907.6K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $109,164,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1556.76 |
| 52 Week Low | $17.59 | $0.44 |
| 52 Week High | $20.12 | $2.97 |
| Indicator | NPFD | IPSC |
|---|---|---|
| Relative Strength Index (RSI) | 40.46 | 50.84 |
| Support Level | $18.51 | $2.13 |
| Resistance Level | $19.37 | $2.45 |
| Average True Range (ATR) | 0.20 | 0.17 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 32.27 | 50.46 |
Nuveen Variable Rate Preferred&Income is a diversified, closed-end management investment company. Its investment objective is to provide a high level of current income and total return. The fund invests a majority of its assets in variable-rate preferred securities and other variable-rate income-producing securities. The rest of its investments can be made in contingent capital securities or contingent convertible securities, convertible securities, corporate debt securities, U.S. government securities, residential and commercial mortgage-backed securities, fixed-rate preferred securities, senior loans and loan participations and assignments, sovereign debt instruments, debt securities issued by supranational agencies, and/or taxable and tax-exempt municipal bonds.
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.